[OADPS] Performance Measures Reporting for OD2A in States Cooperative Agreement

OD2A-S Performance Measures: Quick Reference Guide for Qualitative Data
This document serves as a Quick Reference Guide to qualitative data that will be entered into Partner’s Portal
including data for one qualitative performance measure, HE_Impact, as well as contextual and data quality questions
for all eight performance measures. All information presented in this document can be found within the OD2A-S
Performance Measures Technical Guidance v2.3 May 2025). Additionally, this companion document can be used
alongside the Excel Reporting Tool, which will capture quantitative data on seven performance measures. All data will
be submitted to CDC within the Performance Measures Module of Partner’s Portal.

Qualitative Performance Measure: HE_Impact
HE_Impact
Reporting
Specifications

Impactful practices for improving access to care and treatment for disproportionately
affected populations
The following format is recommended for reporting this qualitative indicator:
1. Brief description of the implemented and/or tailored (adapted to specific cultural, linguistic,
environmental, or social needs of populations) evidence-based intervention or innovative practice
(including setting and whether navigators were included if applicable) and how these compare to
previous efforts.
2. How access to care or treatment has been improved, and what new/existing community assets
were leveraged.
3. Specific populations disproportionately affected by overdose and underserved with care and
treatment programs are impacted by efforts (if tracked).
4. This is optional. Any other outcomes that were improved (provides recipients the option to expand
beyond access to care and include any other outcomes, for example, retention in care, decreased
opioid use).
The length of the narrative should be succinct, but each impactful practice* should have a descriptive
paragraph if more than one is outlined.

1

Contextual and Data Quality Questions
Label Name
HE_Impact

HE_Activities

HR_Encounters

HR_Naloxone

Performance
Measure

Contextual Questions

Impactful practices for
improving access to
care and treatment for
disproportionately
affected populations

1.

Number of health
impact overdose
prevention interventions
focused on
disproportionately
affected populations
implemented with
OD2A funding
Number of harm
reduction service
encounters at OD2A
funded or supported
organizations

1.

Number of naloxone
doses distributed by
OD2A funded or
supported organizations

2.

Data Quality Questions

What barriers prevent achieving access to care
and treatment for SUD?
What facilitators support achieving access to
care and treatment for SUD?

1.

Please describe the activities in this
performance measure, for whom they were
intended, and how the activities were
implemented and/or tailored (e.g., linguistically,
culturally) for disproportionately affected
populations?

1.

1.

What are the barriers for people accessing
harm reduction services in your jurisdiction?
2. What are the facilitators for people accessing
harm reduction services in your jurisdiction?
3. What types of services are included?
4. Please estimate the proportion of harm
reduction service encounters that occurred:
___% at brick-and-mortar locations
___% via mobile-based outreach services
___% via mail-based delivery
___% other (please specify)

1.

1.

1.

2.

What are barriers to accessing or receiving
naloxone?
What are facilitators to accessing or receiving
naloxone?

2.

2.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
How many OD2A-funded
organizations are
included in the data
submitted?
If you selected “other”
type of organizations in
the reporting tool, please
describe.
Describe any issues or
concerns that impact the

2

3.

How did you use OD2A Funds to distribute
naloxone (e.g., staffing to distribute, vending
machines)?
4. (Optional). Describe mechanisms used to
distribute naloxone (e.g., mail in, handoffs).
LTC_Navigators

Number of navigators
who link PWUD to care
and harm reduction
services via warm
handoffs

LTC_Referrals

Number of referrals to
care and harm
reduction services

1.

Describe what types of navigators are included
in the data reported (e.g., certified peer recovery
specialists, peer support specialists, case
managers, patient navigators, community
health workers, persons with lived experience,
etc.).
2. Describe methods to support navigators,
including average hourly pay, benefits, and
additional supports (e.g., trauma, wellness,
emotional/psychological support, infrastructure
such as a phone) to help retain them.
Types of Impactful Referrals
1. This contextual question is optional. If you have
other OD2A funded or supported referrals
beyond referrals to MOUD, behavioral
treatment only (without MOUD), and harm
reduction services. Please describe the “other”
types of referrals.
Reporting Partners
2. Approximately, what % of healthcare facilities
(e.g., hospitals, emergency departments, and
other clinical settings) reported data to your
jurisdiction for this performance measure? (If %
not available, report total number of healthcare
facilities that reported)
3. Approximately, what % of EMS agencies
reported data to your jurisdiction for this
performance measure? (If % not available,
report total number of EMS agencies that
reported).
4. Approximately, what % of carceral settings (e.g.,
prisons and jails), reported data to your

quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).
1.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).

1.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).

3

HS_Training

Number of clinicians
who received training
on implementing the
“2022 CDC Clinical
Practice Guidelines for
Prescribing Opioids for
Pain”

HS_SUD_Protocols

Number of
health/clinical settings
implementing or
improving protocols
and/or policies for
evidence-based SUD
treatment or referrals

jurisdiction for this performance measure? (If %
not available, report total number of carceral
settings that reported).
5. Approximately, what % of harm reduction
settings (e.g., SSPs) reported data to your
jurisdiction for this performance measure? (If %
not available, report total number of carceral
settings that reported).
1. Describe the trainings including the title,
number offered, length, who conducted them,
and where the training occurred.
2. This contextual question is optional. What
populations are served by the clinicians who
were trained?
3. What are barriers to effectively training
clinicians on the “2022 CDC Clinical Practice
Guideline”?
4. What are facilitators to effectively training
clinicians on the “2022 CDC Clinical Practice
Guideline”?
1. Describe how access to MOUD for healthcare
settings has changed since implementing
policies or protocols.
2. Describe the partnerships for SUD referral with
the health settings included in this indicator.
What steps were taken to develop and build
the partnerships for SUD referrals?

1.

Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).

1.

What types of health
settings are included in
the reported data?
Describe any issues or
concerns that impact the
quality of the data shared
(e.g., data completeness,
data accuracy,
facilitators/barriers for
collection and reporting).

2.

4